×
About 583 results

ALLMedicine™ Adult-onset Still's Disease Center

Research & Reviews  225 results

Circulating regulatory T cells in adult-onset Still's disease: focusing on their plasti...
https://doi.org/10.1111/cei.13648
Clinical and Experimental Immunology; Shimojima Y, Ichikawa T et. al.

Jul 29th, 2021 - We investigated the characteristics of regulatory T cells in adult-onset Still's disease (AOSD), with a focus on their plasticity, stability, and relationship with disease severity. The proportion of circulating CD4+CD25+FoxP3+ cells (Tregs) and i...

An update on the pathogenic role of IL-6 in rheumatic diseases.
https://doi.org/10.1016/j.cyto.2021.155645
Cytokine Kaneko Y, Takeuchi T

Jul 26th, 2021 - Interleukin (IL)-6 is a pleiotropic cytokine that is involved in the pathogenesis of various rheumatic diseases. Direct inhibition of the IL-6 pathway by an anti-IL-6 receptor or inhibiting the ligand itself has proved to be efficacious in the tre...

Clinical characteristics of macrophage activation syndrome in adult-onset Still's disease.
https://www.ncbi.nlm.nih.gov/pubmed/34251315
Clinical and Experimental Rheumatology; Gao Q, Yuan Y et. al.

Jul 13th, 2021 - Macrophage activation syndrome (MAS) is considered the most severe complication of adult-onset Still's disease (AOSD). This retrospective observational study was conducted to explore the clinical characteristics of AOSD-MAS patients, the risk fact...

An Update on the Pathogenic Role of Macrophages in Adult-Onset Still's Disease and Its ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238602
Journal of Immunology Research; Chen PK, Chen DY

Jul 10th, 2021 - Increasing evidence indicates a pivotal role of macrophages in innate immunity, which contributes to the pathogenesis of adult-onset Still's disease (AOSD). Despite the available reviews that summarized the pathogenic role of proinflammatory cytok...

The implication of interferon-γ-producing immunocompetent cells for evaluating disease ...
https://doi.org/10.1111/1756-185X.14171
International Journal of Rheumatic Diseases; Ichikawa T, Shimojima Y et. al.

Jul 10th, 2021 - To investigate the relationship between interferon-γ (IFN-γ), IFN-γ-producing immunocompetent cells, their related cytokines, and the clinical features in adult-onset Still's disease (AOSD). Twenty-five patients with AOSD before initiating treatme...

see more →

Clinicaltrials.gov  3 results

Multi-center Registration Study of Adult Onset Still's Disease in Chinese Population
https://clinicaltrials.gov/ct2/show/NCT03651193

Nov 26th, 2018 - Backgrounds: Adult-onset Still's disease (AOSD) is a rare systemic clinical syndrome of unknown etiology. Its pathogenesis is complex, often thought to be affected by infection, genetic and immune factors. Due to the low incidence of adult Still's...

Admission of Adult-onset Still Disease Patients in the ICU
https://clinicaltrials.gov/ct2/show/NCT03276650

Sep 20th, 2018 - Since its first description in 1971, diagnosing adult-onset Still's disease (AOSD), a rare multisystemic disorder considered as a multigenic autoinflammatory syndrome, remains challenging. Rarely, AOSD may present severe systemic manifestations an...

Treatment of Refractory Adult-onset Still's Disease With Anakinra: a Randomized Study
https://clinicaltrials.gov/ct2/show/NCT01033656

Mar 6th, 2017 - Product: Kineret (anakinra) Comparative agents: Methotrexate or azathioprine or leflunomide or cyclosporin A or sulphasalazine Protocol title: An open, randomized study treating refractory adult-onset Still's disease with IL-1ra anakinra (Kineret,...

see more →

News  5 results

FDA Approves Canakinumab (Ilaris), First Drug for Adult-Onset Still's Disease
https://www.medscape.com/viewarticle/932625

Jun 19th, 2020 - The Food and Drug Administration has expanded the indications for canakinumab (Ilaris) to include all patients with active Still's disease older than 2 years, adding adult-onset Still's disease (AOSD) to a previous approval for juvenile-onset Stil...

IL-6 for Adult Still's: A New Option?
https://www.medpagetoday.com/rheumatology/generalrheumatology/75699

Oct 14th, 2018 - Action Points Some clinical benefits were seen among patients with adult-onset Still's disease treated with tocilizumab (Actemra) in a small clinical trial, but the study's primary endpoint was not met. During the double-blind part of the trial, t...

Blocking IL-18 Shows Promise in Still's Disease
https://www.medpagetoday.com/rheumatology/arthritis/71381

Feb 26th, 2018 - Action Points Tadekinig alfa, a recombinant human IL-18 binding protein, showed promise as a novel strategy for the treatment of refractory adult-onset Still's disease (AOSD), in a phase II, European, multicenter study of 23 patients. Note that AO...

Steroids and DMARDs Needed in Adult-Onset Still's
https://www.medpagetoday.com/rheumatology/arthritis/21574

Aug 7th, 2010 - Action Points Explain to interested patients that in this study of patients with adult-onset Still's disease (aka systemic juvenile idiopathic arthritis), treatment with NSAIDs alone was usually not effective whereas steroids usually were. Note th...

Anakinra Promising in Pediatric Inflammation
https://www.mdedge.com/rheumatology/article/44666/pediatrics/anakinra-promising-pediatric-inflammation
Kate Johnson

Response to anakinra treatment was rapid and sustained in most patients with adult-onset Still's disease and in a “significant proportion” of patients with systemic-onset juvenile idiopathic arthritis, according to a study. The results suggest the.

see more →